Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

May 31, 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

May 25, 2023

Ascendis Pharma to Host Oncology Program Update on May 31

May 13, 2023

Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023

May 3, 2023

Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference

May 1, 2023

U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism

April 27, 2023

Ascendis Pharma Reports First Quarter 2023 Financial Results

April 13, 2023

Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27

April 3, 2023

Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023

April 3, 2023

Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism

March 10, 2023

Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© June 2023 Ascendis Pharma